| Primary | Percentage of Participants With Pathological Complete Response (pCR) | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria: 1) the primary tumor was Grade 5 (no malignant cells identified at the location of the primary tumor (ductal carcinoma in situ may be present); 2) no involvement was identified in the lymph nodes; 3) the tumour size at evaluation of the surgical piece was 0 centimeters (cm); and 4) the pathological staging of the tumour from the surgical piece was pT0pN0pM0, the stage is not applicable (NA). It will only be considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. | Population evaluable for anatomopathological response: participants who satisfied all inclusion criteria and none of the exclusion criteria, received at least 2 cycles of chemotherapy treatment, and were evaluated pathologically. | Posted | | Number | 95% Confidence Interval | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Secondary | Percentage of Participants With Objective Clinical Response | Overall clinical response is the best response obtained through physical examination and/or radiological tests after completion of chemotherapy cycles. The percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) and was categorized as clinical response (CR+PR) or clinical benefit (CR+PR+ no change [NC]). Per RECIST, CR was defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of the longest diameter (LD) of all target lesions. No unequivocal progression of non-target disease. No new lesions. Complete and partial responses must have been confirmed no less than 4 weeks after the criteria for response were first met. | | Posted | | Number | 95% Confidence Interval | percentage of participants | | Within 28 days of enrollment, Weeks 12 and 24 | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With Breast-Conserving Surgery | Breast-conserving surgery was defined as lumpectomy + lymphadenectomy (LA), segmentectomy + LA, quadrantectomy + LA, or other (including sentinal node extirpation tumorectomy). | ITT population; only those participants who underwent surgery were included in the analysis | Posted | | Number | | percentage of participants | | Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Proliferation of Ki67 | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. Biomarker Ki67 proliferation was defined as low (less than [<]15% ) and high (≥15%). | Population evaluable for anatomopathological response with evaluable levels of the specified biomarker; data were missing for 2 participants. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Kisspeptin (KISS1) Amplification | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by KISS1 Protein Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Vascular Endothelial Growth Factor Receptor (VEGFR) Amplification | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEFGR amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by VEGFR Protein Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGFR protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Hypoxia Inducible Factor (HIF) Protein Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. HIF protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Endothelial Nitric Oxide Synthase (ENOS) Protein Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. ENOS protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Angiotension Protein Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. Angiotensin protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Vascular Endothelial Growth Factor (VEGF) Gene Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGF gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by VEGFR Gene Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGFR gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Phosphorylated AKT (pAKT) Gene Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. pAKT gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by HIF Gene Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. HIF gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Insulin-Like Growth Factor (IGF) Gene Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. IGF gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by ENOS Gene Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. ENOS gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Phosphorylated MAP Kinase (pMAPK) Gene Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. pMAPK gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by Angiotensin II Receptor Type I (AGTR) Gene Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. AGTR gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by KISS1 Gene Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |
| Secondary | Percentage of Participants With pCR by RKISS1 Gene Expression | The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. RKISS1 gene expression was defined as below the housekeeping reference level (>0), above the housekeeping reference level (<0), or equal to the housekeeping reference level (0). | Only those participants evaluated for the specified biomarker were included in the analysis. | Posted | | Number | | percentage of participants | | After Week 24 (surgery) | | | | ID | Title | Description |
|---|
| OG000 | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. |
| |